ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

LTRN Lantern Pharma Inc

5.23
-0.23 (-4.21%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lantern Pharma Inc LTRN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.23 -4.21% 5.23 16:38:25
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.55 5.42 6.04 5.50 5.46
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202407:00BWLantern Pharma Launches “Webinar Wednesdays” Featuring..
22/4/202407:12BWLantern Pharma Receives Regulatory Approval to Expand..
18/3/202415:02BWLantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
18/3/202406:12IHMARKETNEWSAnticipation Builds on Wall Street for Federal Reserve’s..
15/3/202407:00BWLantern Pharma Announces Initial Patients Dosed in..
11/3/202406:30BWLantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
05/3/202407:01BWLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
04/3/202407:01BWLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
29/2/202420:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202407:01BWLantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
19/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202406:30BWStarlight Therapeutics, a Subsidiary of Lantern Pharma..
29/12/202315:05EDGAR2Form 8-K - Current report
01/12/202305:02EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202305:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202307:00BWFDA Grants Lantern Pharma Orphan Drug Designation for Drug..
24/11/202315:05EDGAR2Form 8-K - Current report
08/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:05EDGAR2Form 8-K - Current report
08/11/202315:01BWLantern Pharma Reports Third Quarter 2023 Financial Results..
01/11/202307:00BWLantern Pharma to Report Third Quarter 2023 Operating &..
20/10/202316:25EDGAR2Form 8-K - Current report
10/10/202307:00BWLantern Pharma to Present at the ThinkEquity Conference on..
03/10/202307:00BWLantern Pharma Announces Publication in Clinical Cancer..
25/9/202307:30BWLantern Pharma Announces First Patient Dosed in the Phase 1..
18/9/202308:00BWLantern Pharma Receives IND Clearance from FDA Enabling..
31/8/202307:00BWLantern Pharma to Present Data Highlighting the Anti-Tumor..
28/8/202307:00BWLantern Pharma Expands AI Capabilities of RADR® Platform to..
14/8/202307:30BWLantern Pharma Receives Notice of US Patent Allowance for..
09/8/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:05EDGAR2Form 8-K - Current report
09/8/202315:01BWLantern Pharma Reports Second Quarter 2023 Financial Results..
02/8/202307:00BWLantern Pharma to Report Second Quarter 2023 Operating &..
17/7/202307:00BWLantern Pharma to Participate and Present at Multiple..
26/6/202307:30BWOncotarget Publishes New Data by Lantern Pharma, an AI..
12/6/202307:30BWLantern Pharma Receives FDA Clearance of IND Application for..
08/6/202308:00BWLantern Pharma Leverages AI Platform, RADR®, to Develop..
17/5/202307:00BWLantern Pharma to Present at the Lytham Partners Spring 2023..
09/5/202315:01BWLantern Pharma Reports First Quarter 2023 Financial Results..
03/5/202308:00PRNUSLantern Pharma Selects REPROCELL USA to Provide Support for..
02/5/202315:01BWLantern Pharma to Report First Quarter 2023 Operating &..
02/5/202306:30BWLantern Pharma Develops Top-Ranked AI Algorithms to Predict..

Su Consulta Reciente

Delayed Upgrade Clock